# Recombinant Human Erythropoietin Improve Neurodevelopmental Outcomes in Extremely Preterm Infants

> **NCT02745990** · NA · UNKNOWN · sponsor: **Huiqing Sun** · enrollment: 440 (estimated)

## Conditions studied

- Developmental Disabilities

## Interventions

- **DRUG:** Recombinant human erythropoietin
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT02745990
- **Lead sponsor:** Huiqing Sun
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 440 (ESTIMATED)
- **Last updated:** 2021-08-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02745990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02745990, "Recombinant Human Erythropoietin Improve Neurodevelopmental Outcomes in Extremely Preterm Infants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02745990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*